Nielsen, J, Young, C, Ifteni, P, Kishimoto, T, Xiang, Y, Schulte, P, et al. Worldwide differences in regulations of clozapine use. CNS Drugs
2016; 30: 149–61.
Deng, C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am
2013; 42: 545–63.
Jin, H, Meyer, JM, Jeste, DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res
2004; 71: 195–212.
Foley, DL, Mackinnon, A, Morgan, VA, Watts, GF, Castle, DJ, Waterreus, A, et al. Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. Lancet Psychiatry
2015; 2: 1092–8.
Stahl, S, Mignon, L, Meyer, J. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Acta Psychiatr Scand
2009; 119: 171–9.
Smith, GC, Zhang, ZY, Mulvey, T, Petersend, N, Lach, S, Xiuc, P, et al. Clozapine directly increases insulin and glucagon secretion from islets: implications for impairment of glucose tolerance. Schizophr Res
2014; 157: 128–33.
Contreras-Shannon, V, Heart, DL, Paredes, RM, Navaira, E, Catano, G, Kaushal Maffi, S, et al. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS ONE
2013; 8 (suppl 3): e59012.
Duiverman, ML, Cohen, D, Van Oven, W, Nioboer, P. A patient treated with olanzapine developing diabetes de novo: proposal for hyperglycaemia screening. Neth J Med
2007; 65: 346–8.
Madsen, K. Fatal hypertriglyceridaemia, acute pancreatitis and diabetic ketoacidosis possibly induced byquetiapine. Case Rep
Takahashi, M, Ohishi, S, Katsumi, C, Moriya, T, Miyaoka, H. Rapid onset of quetiapineinduced diabetic ketoacidosis in an elderly patient. Pharmacopsychiatry
2005; 38: 183–4.
Mustafa, F, Burke, J, Abukmeil, S, Scanlon, J, Cox, M. ‘Schizophrenia past clozapine’: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry
2014; 48: 11–4.
Nielsen, J, Correll, C, Manu, P, Kane, J. Termination of clozapine treatment due to medical reasons. J Clin Psychiatry
2013; 74: 603–13.
Taylor, D, Douglas-Hall, P, Olofinjana, B, Whiskey, E, Thomas, A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry
2009; 194: 165–7.
Meyer, JM, Mao, Y, Pikalov, A, Cucchiaro, J, Loebel, A. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol
2015; 30: 342–50.
Taylor, D, Kapur, S. The Maudsley Prescribing Guidelines in Psychiatry.
Krakowski, M, Czobor, P, Citrome, L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res
2009; 110: 95–102.
Mayfield, K, Siskind, D, Winckel, K, Russell, AW, Kisel, S, Smith, G, et al. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol
2016; 30 (suppl 3): 227–36.